TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10723239
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose (S-1 group, n = 13; BHAC 150 mg/m2 1-7 day, DNR 30 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Study: 10723239
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose (S-2 group, n = 16; BHAC 200 mg/m2 1-7 day, DNR 40 mg/m2 1-3 day, 6MP 70 mg/m2 1-7 day)
Study: 3068400
Drug: Streptokinase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase treatment (1,000,000 units over 60 min)
Study: 3068400
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase administration (120,000‐180,000 units over 60‐90 min)
Study: 3068400
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intracoronary routes of administration
Study: 25420736
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L PEG + bisacodyl 10 mg
Study: 25420736
Drug: PEG only
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG only group (4 L PEG)
Study: 23011562
Drug: Phenylephrine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine bolus (120 μg)
Study: 23011562
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (120 μg/min)
Study: 2544119
Drug: Etomidate infusion
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate infusion (16.8 +/- 3.0 mg.kg‐1.min‐1)
Study: 25854635
Drug: Levetiracetam 500
Normalized name: levetiracetam 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam 500 mg/day
Study: 11823112
Drug: Levetiracetam 2000
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam 2000 mg/day
Study: 21863617
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of ephedrine (50 mg/500 ml of Ringer solution)
Study: 21863617
Drug: Preoperative hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative hydration with 20 ml/kg of Ringer solution
Study: 21863617
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of ephedrine
Study: 11564387
Drug: Propafenone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (mean daily dose 13 +/- 1.5 mg/kg)
Study: 11564387
Drug: Sotalol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (mean daily dose 3 +/- 0.4 mg/kg)
Study: 25747197
Drug: Trebananib 10
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib 10 mg/kg once weekly plus paclitaxel and bevacizumab (Arm A)
Study: 25747197
Drug: Trebananib 3
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib 3 mg/kg once weekly plus paclitaxel and bevacizumab (Arm B)
Study: 25747197
Drug: Open-label trebananib
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label trebananib 10 mg/kg once weekly plus paclitaxel (Arm D)
Study: 25747197
Drug: Open-label trebananib
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label trebananib 10 mg/kg once weekly (Arm D) with high exposure
Study: 25747197
Drug: Open-label trebananib
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label trebananib 10 mg/kg once weekly (Arm D) with low exposure
Study: 23167499
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy exercises
Study: 20112576
Drug: Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbs promoting blood circulation and removing blood stasis (Caesalpinia Sappan 10 g, Ligusticum Chuanxiong 6 g, Frankincense 6 g, Angelica 10 g, Safflower 6 g, Myrrh 6 g, Ground Beetle 10 g, Araliaceae 3 g, Radix Paeoniae Rubra 10 g, Pericarpium Citri Reticulatae 5 g, Lawn Pennywort Herb 15 g, Manis Pentadactyla 10 g, Corydalis Yanhusuo 10 g, Rhizoma Drynariae 15 g) taken orally for 10 days, and external application of traditional medicine for fuming and washing limbs twice daily.
Study: 20112576
Drug: Placebo of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of the same color for oral use and external application, with the same delivery times and therapy duration as the treatment group.
Study: 7986160
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride (nonselective beta 1‐ and beta 2‐blocker)
Study: 7986160
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate (selective beta 1‐blocker)
Study: 2623708
Drug: Preventive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive care program in dental practice, details on dosage and duration not specified.
Study: 1184719
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg iv)
Study: 1184719
Drug: Apomorphine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (selective dopamine receptor agonist)
Study: 24221463
Drug: 33‐gauge injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33‐gauge injection device without a speculum
Study: 21485071
Drug: Chinese drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drugs for supplementing qi-blood and nourishing Gan-Shen (Cuhuangti Granule and Jinghou Zengzhi Granule)
Study: 12742279
Drug: Ximelagatran 20
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 20 mg twice daily
Study: 12742279
Drug: Ximelagatran 40
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 40 mg twice daily
Study: 12742279
Drug: Ximelagatran 60
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 60 mg twice daily
Study: 26699670
Drug: PEAS-Diet (interview-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEAS-Diet (interview-administered version)
Study: 24885132
Drug: Surgical antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical antimicrobial prophylaxis administered in the anesthesia room (75 to 30 minutes before incision)
Study: 24885132
Drug: Surgical antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical antimicrobial prophylaxis administered in the operating room (less than 30 minutes before incision)
Study: 22457015
Drug: Clevidipine (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine (2.0 mg/h, titrated to target dose up to 16.0 mg/h)
Study: 17431817
Drug: Phenylalanine-free amino
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine-free amino acid supplements without LCPUFA
Study: 7625106
Drug: Recombinant DNA
Normalized name: Recombinant DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant DNA yeast-derived HB vaccine booster dose
Study: 7625106
Drug: Four doses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four doses of primary immunization
Study: 7625106
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of primary immunization
Study: 7625106
Drug: Age-related antibody
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-related antibody levels
Study: 357071
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg 3 times a day
Study: 357071
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg 3 times a day
Study: 357071
Drug: Metoclopramide 30
Normalized name: metoclopramide 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 30 mg daily
Study: 29533252
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy
Study: 20931060
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts (ORS)
Study: 31264950
Drug: Intravenous contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous contrast agent administration (CT angiography)
Study: 31264950
Drug: Intra-arterial contrast
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial contrast agent administration (catheterization)
Study: 23831913
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Q10 daily for 12 weeks
Study: 21246788
Drug: Propiverin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverin 30 mg daily
Study: 21246788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propiverin 30 mg daily and tamsulosin 0.4 mg daily
Study: 17576207
Drug: Oral delayed
Normalized name: Urimax, oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delayed release granules
Study: 17576207
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL rectal foam
Study: 17576207
Drug: Rectal delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal delivery of 5‐ASA
Study: 9869017
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine 10-40 mg daily, captopril 12.5-50.0 mg daily, hydrochlorothiazide 12.5-50.0 mg daily)
Study: 8005305
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist therapy for 12 weeks
Study: 22451196
Drug: Aripiprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (10 mg)
Study: 28334771
Drug: Degarelix 360
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 360 mg every 84 days
Study: 28334771
Drug: Degarelix 480
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 480 mg every 84 days
Study: 25287168
Drug: 280 mg
Normalized name: levodopa 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg of acid‐resistant lipase
Study: 18535812
Drug: SCIT (Subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCIT (Subcutaneous Immunotherapy)
Study: 18535812
Drug: SLIT (Sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT (Sublingual Immunotherapy)
Study: 6139628
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D or alfacalcidol treatment; specific dosage and duration not mentioned.
Study: 22476240
Drug: Pregabalin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (100 mg preoperatively, then 50 mg every 12 hrs)
Study: 19608565
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa) for final oocyte maturation
Study: 17890944
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy without thalidomide
Study: 17890944
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with thalidomide
Study: 27525826
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment for 4 weeks, using two acupoints: Baihui and Shenting
Study: 27525826
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified what treatment they received)
Study: 15939567
Drug: Delayed-treatment control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-treatment control condition
Study: 18462423
Drug: IPL plus
Normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPL plus BTX (8 U total dose, 0.1 mL intradermal injections in one cheek)
Study: 16378562
Drug: No modifications
Approvals — FDA: no, EMA: no, PMDA: no
Description: No modifications to drug treatment
Study: 16378562
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of antihypertensive drugs taken
Study: 16378562
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of antihypertensive drug modifications
Study: 8629830
Drug: Adjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapies (not specified)
Study: 1670907
Drug: Upright tilt-table
Normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upright tilt-table test with isoproterenol infusion (1 to 3 micrograms/minute)
Study: 1670907
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with beta-blockers, disopyramide, transdermal scopolamine, or hydroflurocortisone
Study: 31132897
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% desoximetasone spray with twice daily phone call reminders
Study: 26956140
Drug: Single SPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SPI visit with a diabetes treatment video
Study: 16259540
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 or 20 mg/day)
Study: 15493437
Drug: Visual attention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Visual attention therapy (12 one-hour sessions, computer-based)
Study: 11101481
Drug: Phylloquinone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phylloquinone (1000 microg daily for 2 weeks)
Study: 8956929
Drug: Tiagabine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (30 mg/day)
Study: 8956929
Drug: Tiagabine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (mean 65.7 mg/day, range 30-80 mg/day)
Study: 8956929
Drug: Tiagabine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (mean 67.6 mg/day, range 24-80 mg/day)
Study: 1488558
Drug: RU 41740
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 41740 long-term treatment for 6 months
Study: 1488558
Drug: RU 41740
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 41740 standard treatment for 3 months
Study: 31437659
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge before training sessions
Study: 31437659
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge before training sessions
Study: 24650860
Drug: Sequential intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential intervention (n=552)
Study: 19793169
Drug: 1 liter
Normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL GEL [Hand Sanitizer Cristal Prime 1 liter]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 liter PEG with 200 mg dimethylpolysiloxane 3 hours before CE
Study: 15715188
Drug: Oral clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clarithromycin (Klaricid XL) once-daily for 3 months
Study: 10090328
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (15 p.p.m.)
Study: 10090328
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without inhaled nitric oxide)
Study: 7751833
Drug: Buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (10 or 15 mg)
Study: 7751833
Drug: Low-dose training
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose training phase
Study: 7751833
Drug: Self-reported effects
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported effects of both drugs
Study: 399857
Drug: Increasing weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Increasing weekly injections of house dust mite extract for 18 weeks followed by monthly injections to complete 18 months of treatment
Study: 399857
Drug: Similar injections
Normalized name: Antigonadotropins and similar agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar injections for 18 weeks followed by placebo injections up to 18 months
Study: 399857
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections for 18 months
Study: 30871894
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no physiotherapy treatment)
Study: 27865639
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Nitinol stent (NS) with cryoplasty (CR) and drug-coated balloon
Study: 23504694
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg once daily) and asunaprevir (600 mg twice daily) for 24 weeks (Group A)
Study: 23504694
Drug: Daclatasvir (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir (60 mg once daily) and asunaprevir (600 mg twice daily) with peginterferon alfa-2a and ribavirin for 24 weeks (Group B)
Study: 19622986
Drug: Birth weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth weight below 4,000 g
Study: 12508046
Drug: Mandibular two-implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular two-implant retained overdentures (IOD)
Study: 8857075
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of budesonide (2 mg in 100 ml fluid)
Study: 8857075
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of budesonide (2 mg in gelatine capsule)
Study: 29879048
Drug: Control (false
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (false TAES followed by saline injection after 30 minutes)
Study: 29879048
Drug: TAES (TAES
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAES (TAES followed by saline injection after 30 minutes)
Study: 29879048
Drug: Sufentanil (false
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (false TAES followed by low‐dose sufentanil (0.1 μg/kg) injection after 30 minutes)
Study: 29879048
Drug: Sufentanil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plus TAES (TAES followed by low‐dose sufentanil injection after 30 minutes)
Study: 19467896
Drug: PRP administered
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP administered to lower responders
Study: 16336071
Drug: Comprehensive family‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive family‐based behavioral treatment program
Study: 16336071
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment incorporating reinforcing children for engaging in alternative behaviors to eating
Study: 12490092
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group received a primary dose of 1000 units of the new vaccine.
Study: 12490092
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group received a primary dose of 500 units of the new vaccine.
Study: 12490092
Drug: Havrix group
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix group received a primary dose of 1440 enzyme-linked immunosorbent assay units of Havrix.
Study: 12490092
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (1000 units) at month 6.
Study: 12490092
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (1000 units) one month after booster dose.
Study: 2205290
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms ethinyl oestradiol daily by mouth for 10 days
Study: 2205290
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily by mouth for 10 days
Study: 29712515
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 30 IU of oxytocin started before uterine incision (Group I)
Study: 29712515
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 30 IU of oxytocin started after clamping the umbilical cord (Group II)
Study: 23636616
Drug: Asthmatic children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthmatic children (AG) without supplements
Study: 21510853
Drug: Background stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background stroke care (limited, no thrombolytic therapy)
Study: 17360872
Drug: malaria vaccine
Normalized name: malaria vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: malaria vaccine regimen FP9 ME‐TRAP/MVA ME‐TRAP
Study: 17360872
Drug: rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabies vaccine
Study: 11157317
Drug: High isoflavone
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High isoflavone diet (132 +/- 22 mg isoflavones/d)
Study: 11157317
Drug: Low isoflavone
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low isoflavone diet (65 +/- 11 mg isoflavones/d)
Study: 11157317
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (7.1 +/- 1.1 mg isoflavones/d)